# Entera Bio Ltd.

**ENTX**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001638097

**D**

**fourth fifth of 369 graded peers in healthcare**

rank 242 of 369; percentile 65.5; sampling error 2.5 points; lower is stronger

A B C D E

**D, the sloth**



| Scoreboard | |
|---|---|
| **Profitability** | C<br>percentile 54.4 |
| **Solvency** | C<br>percentile 50.0 |
| **Growth and financing** | C<br>percentile 54.8 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $16.0M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | degenerate inputs<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 27, 2026<br>230 days before the rescan; latest periodic filing 10-Q received Nov 6, 2026 |
| **Last close** | $3.21<br>2026-11-11; market equity $559.9M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 27, 2026*

Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm. Our pipeline includes differentiated, first-in-class oral peptides targeting PTH(1-34), GLP-1/Glucagon and GLP-2: Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 54.4** | | | | | | |
| Gross profitability | 0.0% | 32.3% | | 95.7 | 365 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Accruals ratio | (32.1%) | (6.6%) | | 13.0 | 801 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *annual revenue must exceed $100,000* | | | | | | |
| **Solvency, sleeve percentile 50.0** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (20.27) | (0.35) | | 73.9 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 6.94x | 2.95x | | 26.2 | 827 | 2025-12-31 |
| **Growth and financing, sleeve percentile 54.8** | | | | | | |
| Revenue growth, three-year compound | (32.1%) | 10.1% | | 92.0 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | 6.8% | 2.2% | | 37.5 | 695 | 2025-12-31 |
| Net share issuance, one year | 2.6% | 2.5% | | 35.1 | 628 | 2026-03-23 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 237 | Integra Lifesciences Holdings Corp. (IART) | 64.1 | D | |
| 238 | Perspective Therapeutics, Inc. (CATX) | 64.4 | D | dilution, short runway, fortress balance sheet |
| 239 | Arvinas, Inc. (ARVN) | 64.7 | D | fortress balance sheet |
| 240 | Organogenesis Holdings Inc. (ORGO) | 64.9 | D | fortress balance sheet |
| 241 | Pulse Biosciences, Inc. (PLSE) | 65.2 | D | |
| 242 | Entera Bio Ltd. (ENTX) | 65.5 | D | degenerate inputs |
| 243 | AIM ImmunoTech Inc. (AIM) | 65.8 | D | late filer, degenerate inputs, distress |
| 244 | Fulgent Genetics, Inc. (FLGT) | 66.0 | D | |
| 245 | Dentsply Sirona Inc. (XRAY) | 66.3 | D | |
| 246 | Caribou Biosciences, Inc. (CRBU) | 66.6 | D | short runway |
| 247 | Angiodynamics Inc. (ANGO) | 66.8 | D | fortress balance sheet |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-11-11 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 0.0% | (1.9%) | 51 |
| Distance from 52-week high | (17.9%) | (27.8%) | 60 |
| EBIT to enterprise value | not computable | (1.6%) | |
| Free cash flow yield | (1.3%) | (1.0%) | 48 |
| Book value to price | 0.49 | 0.27 | 68 |
| Sales to price | 0.00 | 0.29 | 1 |
| Composite equity issuance, five years | not computable | 20.8% | |
| Relative strength against the sector, log excess return | (0.17) | (0.19) | 51 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $265.9M |
| Operating cash flow, four quarters | -$15.8M |
| Months of runway | 202.1 |
| Days since last periodic filing | 6 (10-Q received Nov 6, 2026) |
| Median daily dollar volume, 63 sessions | $937,114 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $0 | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 2 | assets | us-gaap:Assets | $16.0M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 3 | net income | us-gaap:NetIncomeLoss | -$11.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$7.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 5 | assets | us-gaap:Assets | $9.4M | 2024-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 6 | revenue | us-gaap:Revenues | $42,000 | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 7 | current assets | us-gaap:AssetsCurrent | $15.3M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $2.2M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$125.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$11.5M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 11 | book equity | us-gaap:StockholdersEquity | $13.1M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 12 | liabilities | us-gaap:Liabilities | $2.9M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 13 | revenue | us-gaap:Revenues | $181,000 | 2024-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 14 | revenue | us-gaap:Revenues | $0 | 2023-12-31 | 2025-03-28 | 10-K | 25-001112 |
| 15 | revenue | us-gaap:Revenues | $134,000 | 2022-12-31 | 2024-03-08 | 10-K | 24-000881 |
| 16 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $107,000 | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 17 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$6.8M | 2024-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 18 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3,000 | 2024-12-31 | 2026-03-27 | 10-K | 26-001797 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$7.3M | 2023-12-31 | 2025-03-28 | 10-K | 25-001112 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $17,000 | 2023-12-31 | 2025-03-28 | 10-K | 25-001112 |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.5M | 2022-12-31 | 2024-03-08 | 10-K | 24-000881 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $47,000 | 2022-12-31 | 2024-03-08 | 10-K | 24-000881 |
| 23 | depreciation amortization | us-gaap:Depreciation | $30,000 | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 24 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$11.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 25 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 26 | current assets | us-gaap:AssetsCurrent | $9.0M | 2024-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 27 | current liabilities | us-gaap:LiabilitiesCurrent | $1.2M | 2024-12-31 | 2026-03-27 | 10-K | 26-001797 |
| 28 | assets | us-gaap:Assets | $11.8M | 2023-12-31 | 2025-03-28 | 10-K | 25-001112 |
| 29 | assets | us-gaap:Assets | $13.1M | 2022-12-31 | 2024-03-08 | 10-K | 24-000881 |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 46,622,239 | 2026-03-23 | 2026-03-27 | 10-K | 26-001797 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 45,420,676 | 2025-03-20 | 2025-03-28 | 10-K | 25-001112 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.